Skip to content

A Study of Taste- and Olfactory-Evoked Potentials in Patients With Visual Impairment: Taste, Smell, and Vision

A Study of Taste- and Olfactory-Evoked Potentials in Patients With Visual Impairment: Taste, Smell, and Vision

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07707219
Acronym
GOUSTAVIS
Enrollment
50
Registered
2026-07-16
Start date
2026-09-01
Completion date
2028-09-01
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Visual Impairment, Macular Retinal Dystrophy, Peripherical Macular Dystrophy, Peripherical Visual Impairment

Brief summary

Visual impairment, whether central or peripheral, may influence the plasticity of other sensory modalities, such as taste and smell. Taste-evoked potentials (TEPs) and smell-evoked potentials (SEPs)-methods for analyzing brain activity in response to taste and smell stimuli-allow for the objective assessment of these interactions. This approach has already demonstrated its value in the study of cognitive disorders. This study aims to demonstrate an enhancement of taste and smell capabilities that could compensate for specific visual impairments, particularly in situations involving food choices.

Interventions

OTHERTaste and smell evaluation

Determination of taste and smell ability scores using standardized methods (ETOC and Taste Strips)

OTHERRecording of evoked potentials (EP)

A recording of gustatory evoked potentials (GEP) and olfactory evoked potentials (OEP) in response to stimuli consisting of sucrose solution, vanillin, and a combination of the two.

Sponsors

Centre Hospitalier Universitaire Dijon
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult: ≥ 18 years and ≤ 60 years * Individual who has given oral consent * Individual who has been fasting (no food, drink, or tobacco) for at least 1 hour prior to PEG and PEO measurement * No cognitive complaints and normal neurological examination. * Group of patients with visual impairment: A. Central: documented bilateral macular dystrophy (e.g., Stargardt disease, Best disease) with confirmed central scotoma (CV 24.2, 10.2, or 30.2). B. Peripheral: documented bilateral peripheral retinal dystrophy with confirmed peripheral involvement (CV 30-2 or 24-2). • Control group: a person with normal vision and no known ophthalmological abnormalities (normal visual acuity and fundus examination) who is precisely matched by sex and smoking status (former smoker who has quit vs. nonsmoker), and approximately matched by age (± 5 years) to a visually impaired participant included in the study.

Exclusion criteria

For this group: patients with visual impairments: * Individuals who are not enrolled in or eligible for a social security program * Individuals subject to a legal protective measure (guardianship, conservatorship) * Individuals subject to judicial safeguard measures * Adults who are legally incapacitated or unable to give informed consent * Documented COVID-19 infection within the 6 months prior to enrollment * Active smokers (≥1 cigarette per day) or users of any other inhaled substances (water pipe, cannabis, etc.) * Participants following a sugar-free diet * Participants with diabetes, of any type * Participants taking medication (ongoing during the study) that interferes with taste perception • Pregnant or breastfeeding women * Individuals with neurodegenerative diseases (Parkinson's, Alzheimer's) * Individuals with braids, dreadlocks, or any other hairstyle that prevents electrodes from being placed in sufficiently precise locations on the scalp. * Overweight subjects with a BMI ≥ 35 kg/m²

Design outcomes

Primary

MeasureTime frameDescription
Average latency of PEG (Taste-Evoked Potentials) peaksAt the baselineMeasurement of the mean latency of taste-evoked potential peaks in visually impaired patients versus control subjects following purely gustatory stimulation (sucrose).
Average amplitude of PEG (Taste-Evoked Potentials) peaksAt the baselineMeasurement of the mean amplitude of taste-evoked potential peaks in visually impaired patients versus control subjects following purely gustatory stimulation (sucrose).

Countries

France

Contacts

CONTACTPierre-Henry GABRIELLE
pierrehenry.gabrielle@chu_dijon.fr03.80.29.37.56

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026